慢性リンパ性白血病15症例の臨床的観察

書誌事項

タイトル別名
  • Clinical Observation of 15 Patients with Chronic Lymphocytic Leukemia
  • 慢性リンパ性白血病15症例の臨床的観察 免疫学的異常を中心に
  • マンセイ リンパセイ ハッケツビョウ 15 ショウレイ ノ リンショウテキ カンサツ メンエキガクテキ イジョウ オ チュウシン ニ
  • —免疫学的異常を中心に—
  • —Immunological Aspect of C.L.L.—

この論文をさがす

抄録

Fifteen cases of chronic lymphocytic leukemia during the past seven years have been reported and incidence, clinical manifestation, treatment and prognosis were discussed.<br>The results were as follows.<br>1) The incidence was approximately 10 percent of all leukemias. The 15 patients consisted of 6 males and 9 females. All were adults with the mean age of 57.7 at onset.<br>2) Initial symptoms in 8 cases were enlarged lymph nodes, splenomegaly and bleeding tendency which were specific signs of C. L. L, but in other 7 cases the diagnosis of C. L. L. was disclosed by routine hematologic examination. By the initial physical findings of the C. L. L., these cases were divided into four categories: classic type 10 cases, splenomegalic 1 case, specific skin lesions 2 cases, and blood changes-only 2 cases.<br>Several immunological disturbances such as hemolytic anemia with eosinophilia, progressive vaccinia, runting syndrome and various seven infections were recognized. The low level of lyphocyte blastoid transformation with PHA or PWM, negative tuberculin reaction and hypogammaglobulinemia were also observed.<br>3) In most cases, hemoglobin and platelet count levels were within normal limit by initial hematological data. The peripheral leukocyte count was between 30,000 and 100,000 per cmm. Sixty to 99% of these cells were mature lymphocytes which are compatible with normal small lymphocytes.<br>4) Of these 14 cases, were treated with chlorambucil, corticosteroid and vincristine by combination method or alone. The effect of the treatment in 13 cases was evaluated as excellent in 4, good in 5 and slight to none in 4.<br>5) Five years survival rate of these 15 cases was 49.2%.

収録刊行物

  • 臨床血液

    臨床血液 15 (1), 30-37, 1974

    一般社団法人 日本血液学会

詳細情報 詳細情報について

問題の指摘

ページトップへ